44 research outputs found
Diferencias cualitativas en los errores cometidos durante la lectura oral en función del nivel de dificultades del texto.
Get PDFSin resume
Revista complutense de educación
Get PDFResumen basado en el de la publicaciónSe lleva a cabo una revisión general del procedimiento cloze, procedimiento que es ampliamente conocido y utilizado como instrumento de evaluación de la lectura en los países de habla inglesa pero que apenas es conocido y empleado en España. Dicha revisión hace referencia tanto a los aspectos metodológicos relacionados con dicho procedimiento como a los distintos usos para los que puede emplearse en el campo de la evaluación de la lectura.ES
El procedimiento cloze como medida procesal de la comprensión lectora
Get PDFEl procedimiento cloze se utiliza ampliamente hoy en día como una medida del proceso de comprensión lectora en los países de habla inglesa. Sin embargo, hay pocos estudios sobre la validez del procedimiento cloze realizado en idioma español. El presente estudio tiene como objetivo proporcionar algunos datos sobre el uso del procedimiento cloze con sujetos de habla hispana con el fin de contribuir a un mejor conocimiento de esta medida en nuestro país
New synthetic inhibitors of fatty acid synthase with anticancer activity
Get PDFFatty acid synthase (FASN) is a lipogenic enzyme that is highly expressed in different human cancers. Here we report the development of a new series of polyphenolic compounds 5-30 that have been evaluated for their cytotoxic capacity in SK-Br3 cells, a human breast cancer cell line with high FASN expression. The compounds with an IC50 < 50 M have been tested for their ability to inhibit FASN activity. Among them, derivative 30 blocks the 90% of FASN activity at low concentration (4 M), is highly cytotoxic in a broad panel of tumor cells, induces apoptosis, and blocks the activation of HER2, AKT and ERK pathways. Remarkably, 30 does not activate carnitine palmitoyltransferase-1 (CPT-1) nor induces in mice weight loss, which are the main drawbacks of other previously described FASN inhibitors. Thus, FASN inhibitor 30 may aid the validation of this enzyme as a therapeutic target for the treatment of cancer
Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
Full text linkGenetic information has been crucial to understand the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) at diagnosis and at relapse, but still nowadays has a limited value in a clinical context. Few genetic markers are associated with the outcome of T-ALL patients, independently of measurable residual disease (MRD) status after therapy. In addition, the prognostic relevance of genetic features may be modulated by the specific treatment used. We analyzed the genetic profile of 145 T-ALL patients by targeted deep sequencing. Genomic information was integrated with the clinical -biological and survival data of a subset of 116 adult patients enrolled in two consecutive MRD-oriented trials of the Spanish PETHEMA (Programa Espanol de Tratamientos en Hematologia) group. Genetic analysis revealed a mutational profile defined by DNMT3A/ N/KRAS/ MSH2/ U2AF1 gene mutations that identified refractory/resistant patients. Mutations in the DMNT3A gene were also found in the non-leukemic cell fraction of patients with T-ALL, revealing a possible mutational-driven clonal hematopoiesis event to prime T-ALL in elderly. The prognostic impact of this adverse genetic profile was independent of MRD status on day +35 of induction therapy. The combined worse-outcome genetic signature and MRD on day +35 allowed risk stratification of T-ALL into standard or high-risk groups with significantly different 5 -year overall survival (OS) of 52% (95% confidence interval: 37-67) and 17% (95% confidence interval: 1-33), respectively. These results confirm the relevance of the tumor genetic profile in predicting patient outcome in adult T-ALL and highlight the need for novel gene-targeted chemotherapeutic schedules to improve the OS of poor-prognosis T-ALL patients
